OTCMKTS:BRTXQ BioRestorative Therapies (BRTXQ) Stock Price, News & Analysis → $25,000 into $109,616 in two months? (From WealthPress) (Ad) Free BRTXQ Stock Alerts $1.27 -0.07 (-5.22%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.25▼$1.3650-Day Range$1.28▼$1.5052-Week Range$0.00▼$0.06Volume74,859 shsAverage Volume62.17 million shsMarket Capitalization$2.08 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsStock AnalysisChartFinancialsHeadlinesSEC Filings Get BioRestorative Therapies alerts: Email Address Ad WealthPressThe system that called 2023’s top 7 stocks is at it again…Look 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About BioRestorative Therapies Stock (OTCMKTS:BRTXQ)BioRestorative Therapies, Inc. develops therapeutic products using cell and tissue protocols primarily involving adult stem cells. The company's two core programs are related to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program includes a lead cell therapy candidate, BRTX-100 is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow and intended for the non-surgical treatment of painful lumbosacral disc disorders. The BRTX-100 utilizes proprietary technology and involves collecting a patient's bone marrow, isolating and culturing stem cells from the bone marrow, and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient's damaged disc and treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. The company have received authorization from the Food and Drug Administration to commence a Phase 2 clinical trial using BRTX-100to treat persistent lower back pain due to painful degenerative discs. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy in preclinical stage to target obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). In addition, the company provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; and a research agreement with Pfizer, Inc. and the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York. On March 20, 2020, BioRestorative Therapies, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of New York.Read More BRTXQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BRTXQ Stock News HeadlinesApril 16, 2024 | markets.businessinsider.comWhy BioRestorative Therapies Is Rising In Pre-market?April 8, 2024 | msn.comBioRestorative Therapies partners with Galen Patient RecruitmentApril 25, 2024 | Schaeffer’s Research (Ad)Just Released: Insider's Secret to Trading OptionsThis Surprisingly Simple Formula Can Double Your Money Collecting Consistent Profits From The Stock Market Is More Accessible Than You Think A small group of individuals are using a legitimate yet rarely discussed strategy to generate income from the stock market. They're NOT day traders. And they're NOT Wall Street suits either. I'm talking about normal "working stiffs" and retirees generating steady income from a source that 99% of investors completely overlook. This overlooked income source can be yours today.April 3, 2024 | msn.comBioRestorative Therapies files to sell 2.51M shares of common stock for holdersMarch 12, 2024 | forbes.com5 Best Affordable Online Therapy Options Of 2024February 6, 2024 | msn.comBioRestorative Therapies tumbles after private placementFebruary 5, 2024 | markets.businessinsider.comBioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc DiseaseJanuary 12, 2024 | morningstar.comBioRestorative Therapies Inc BRTXApril 25, 2024 | Stansberry Research (Ad)The "Smart Money" Is Ready for May 1st Are You?Former Wall Street VP: "Buy This Stock Now" Five of America's Most Successful Investors Bought Shares in The Same Company. December 4, 2023 | money.usnews.comOccupational Therapy Assistant SalaryOctober 9, 2023 | nasdaq.comBioRestorative Therapies (FRA:9OF) Price Target Increased by 8.74% to 12.19September 1, 2023 | benzinga.comBioRestorative Therapies And 3 Other Stocks Under $3 Insiders Are BuyingJuly 20, 2023 | benzinga.comBioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York StateJuly 11, 2023 | marketwatch.comBioRestorative Therapies Shares Lower Premarket on Stock Offering >BRTXJune 27, 2023 | benzinga.comEXCLUSIVE: BioRestorative Therapies Tells Benzinga Data Monitoring Committee Allows Co's Chronic Lumbar Disc Disease To Continue UnchangedJune 12, 2023 | benzinga.comBioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc DiseaseJune 12, 2023 | benzinga.comEXCLUSIVE: BioRestorative Completes Dosing In Safety Cohort Of Chronic Lower Back Pain TrialMay 31, 2023 | benzinga.comEXCLUSIVE: BioRestorative Therapies Wins License from New York State Department of Health To Act As Tissue Bank for Mesenchymal Stem Cell ProcessingMay 15, 2023 | msn.comEXCLUSIVE: BioRestorative Therapies' ThermoStem For Metabolic Disorders Expected To Receive Fourth Japanese PatentMarch 3, 2023 | marketwatch.comBioRestorative Therapies Shares Rise 40% After U.S. Patent AllowanceFebruary 26, 2023 | nbcnews.comWhat is red light therapy and does it work?January 25, 2023 | benzinga.com2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative TherapiesNovember 9, 2022 | benzinga.comThe NIH Has Given BioRestorative Therapies A Stamp Of ApprovalNovember 2, 2022 | stockhouse.comSee What’s Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies!September 9, 2022 | morningstar.comBioRestorative Therapies Inc BRTX Stock AnalysisJune 30, 2022 | msn.comBioRestorative Shares Fall As Enrolment Initiated in Mid-Stage Chronic Back Pain Drug StudyJune 14, 2022 | benzinga.comBioRestorative Therapies Announces Clinical Site Initiation for the Company's Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)See More Headlines Receive BRTXQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous Health & Allied Services Sub-IndustryN/A Current SymbolOTCMKTS:BRTXQ CUSIPN/A CIK1505497 Webwww.biorestorative.com Phone631-760-8100FaxN/AEmployees8Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$110,000.00 Price / Sales18,930.23 Cash FlowN/A Price / Cash FlowN/A Book Value($0.68) per share Price / Book-1.87Miscellaneous Outstanding Shares1,639,626,000Free FloatN/AMarket Cap$2.08 billion OptionableNot Optionable Beta102.36 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Mark R. Weinreb M.S. (Age 67)Chairman, CEO & Pres Comp: $407.2kMr. Robert Paccasassi (Age 51)VP of Quality & Compliance Comp: $233.95kMr. Francisco J. Silva (Age 45)Chief Scientist and VP of R&D Comp: $310.5kDr. Wayne J. OlanClinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory BoardKey CompetitorsIntellia TherapeuticsNASDAQ:NTLACelldex TherapeuticsNASDAQ:CLDXAstrana HealthNASDAQ:ASTHKeros TherapeuticsNASDAQ:KROSRocket PharmaceuticalsNASDAQ:RCKTView All Competitors BRTXQ Stock Analysis - Frequently Asked Questions How have BRTXQ shares performed in 2024? BioRestorative Therapies' stock was trading at $1.7399 on January 1st, 2024. Since then, BRTXQ shares have decreased by 27.0% and is now trading at $1.27. View the best growth stocks for 2024 here. How do I buy shares of BioRestorative Therapies? Shares of BRTXQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:BRTXQ) was last updated on 4/25/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyFed launches fourth dollar overhaulStansberry ResearchExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersMan Who Predicted 2008: “This Will be Worse.”AltimetryBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioRestorative Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.